Business Segments · Segment operating income
MedSurg and Neurotechnology: — Segment operating income
Stryker MedSurg and Neurotechnology: — Segment operating income decreased by 25.2% to $700M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 16.4%, from $837M to $700M. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementSegment
CategoryProfitability
SignalHigher is better
VolatilityModerate
First reportedQ1 2013
Last reportedQ1 2026May 11, 2026
Rolls up toOperating Income
How to read this metric
An increase signals improved profitability and operational efficiency, while a decrease suggests rising costs or declining pricing power.
Detailed definition
Calculated as the segment's net sales minus its cost of sales, R&D, and SG&A expenses. This metric serves as the primary...
Peer comparison
The standard measure of segment-level profitability used by analysts to compare business units across peers.
Metric ID:
syk_segment_medsurg_and_neurotechnology_segment_operating_incomeHistorical Data
40 periods
| Q2 '21 | Q2 '21 | Q3 '21 | Q3 '21 | Q4 '21 | Q4 '21 | Q1 '22 | Q1 '22 | Q2 '22 | Q2 '22 | Q3 '22 | Q3 '22 | Q4 '22 | Q4 '22 | Q1 '23 | Q1 '23 | Q2 '23 | Q2 '23 | Q3 '23 | Q3 '23 | Q4 '23 | Q4 '23 | Q1 '24 | Q1 '24 | Q2 '24 | Q2 '24 | Q3 '24 | Q3 '24 | Q4 '24 | Q4 '24 | Q1 '25 | Q1 '25 | Q2 '25 | Q2 '25 | Q3 '25 | Q3 '25 | Q4 '25 | Q4 '25 | Q1 '26 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $732M | $702M | $574M | $663M | $819M | $807M | $447M | $630M | $772M | $629M | $808M | $611M | $814M | $961M | $735M | $627M | $965M | $780M | $931M | $859M | $1.26B | $1.2B | $972M | $847M | $1.05B | $903M | $1.09B | $966M | $581M | $1.29B | $837M | $757M | $1.11B | $1.07B | $1.14B | $1.1B | $1.8B | $1.53B | $936M | $700M |
| QoQ Change | — | -4.1% | -18.2% | +15.5% | +23.5% | -1.5% | -44.6% | +40.9% | +22.5% | -18.5% | +28.5% | -24.4% | +33.2% | +18.1% | -23.5% | -14.7% | +53.9% | -19.2% | +19.4% | -7.7% | +46.3% | -4.2% | -19.3% | -12.9% | +24.1% | -14.1% | +20.2% | -11.0% | -39.9% | +121.7% | -35.0% | -9.6% | +47.0% | -4.0% | +6.2% | -2.9% | +63.7% | -15.1% | -38.9% | -25.2% |
| YoY Change | — | — | — | — | — | — | — | — | +5.5% | -14.1% | +40.8% | +6.4% | -0.6% | +17.3% | +64.4% | +40.3% | +25.0% | +1.0% | +15.2% | +6.3% | +54.4% | +47.9% | +32.2% | +15.2% | +8.9% | -6.4% | +16.5% | +3.8% | -53.8% | +2.5% | -13.9% | -22.1% | +5.9% | +1.7% | +4.6% | +1.6% | +210.5% | +163.5% | +11.8% | -16.4% |
Range$447M – $1.8B
CAGR-0.5%
Avg YoY Growth+21.1%
Median YoY Growth+6.4%
Current Streak3 quarters decline
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Stryker's medsurg and neurotechnology: — segment operating income?
- Stryker (SYK) reported medsurg and neurotechnology: — segment operating income of $700M in Q1 2026.
- How has Stryker's medsurg and neurotechnology: — segment operating income changed year-over-year?
- Stryker's medsurg and neurotechnology: — segment operating income decreased by 16.4% year-over-year, from $837M to $700M.
- What does medsurg and neurotechnology: — segment operating income mean?
- The profit earned by the MedSurg and Neurotechnology segment from its core operations.